skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
WT1-A10/AS01B Immunotherapeutic GSK2130579A (Code C78865)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: WT1-A10/AS01B Immunotherapeutic GSK2130579A

Definition: An immunotherapeutic consisting of the recombinant fusion protein WT1-A10 combined with the adjuvant ASO1B with potential immunostimulating and antineoplastic activities. Upon administration, WT1-A10/AS01B immunotherapeutic GSK2130579AWT1 may induce a WT1-specific cytotoxic T-lymphocyte (CTL) response against WT1-expressing tumor cells, resulting in cell lysis and the inhibition of cellular proliferation. The tumor-associated antigen WT1 (Wilms tumor protein-1) is overexpressed in most types of leukemia and in a variety of solid cancers. WT1-A10 is a 292 amino acid recombinant fusion protein consisting of a 12-mer truncated tat sequence (leader sequence) and amino acids number 2-281 of the WT1 sequence; ASO1B consists of a combination of the adjuvants monophosporyl lipd A (MPL) and Q21.

Display Name: WT1-A10/AS01B Immunotherapeutic GSK2130579A

Label: WT1-A10/AS01B Immunotherapeutic GSK2130579A

NCI Thesaurus Code: C78865 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: CL387745  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
WT1-A10/AS01B Immunotherapeutic GSK2130579A

External Source Codes: 
PDQ Closed Trial Search ID 610132
PDQ Open Trial Search ID 610132 (check for NCI PDQ open clinical trial info)

Other Properties:
     Name Value (qualifiers indented underneath)
code C78865
Contributing_Source CTRP
Legacy_Concept_Name WT1_Vaccine_GSK2130579A
Semantic_Type Amino Acid, Peptide, or Protein
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom